# A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

> **NCT07054190** · PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Inavolisib
- **DRUG:** Ribociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT07054190
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-09-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054190, "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07054190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*